Sidley represented Yuhan Corporation in its licensing and collaboration agreement with Gilead Sciences, Inc. to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH), a chronic and progressive liver disease characterized by fat accumulation and inflammation in the liver, which can lead to scarring, or fibrosis, that impairs liver function. Under the agreement, Gilead will acquire global rights to develop and commercialize novel small molecules against two undisclosed targets in all countries, with the exception of the Republic of Korea where Yuhan will retain certain commercialization rights. In connection with this agreement, Yuhan will receive an upfront payment of $15 million and is eligible to receive up to an additional $770 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on future net sales. The deal was led by partner Josh Hofheimer (Los Angeles) with counsel Lauren Grau (Dallas).
Sidley Represents Yuhan Corporation in Licensing and Collaboration Agreement with Gilead Sciences
January 17, 2019